Recent Advances in the Management of Adverse Events Associated with Lorlatinib.
Journal Information
Full Title: Onco Targets Ther
Abbreviation: Onco Targets Ther
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Disclosure The authors declare no conflicts of interest in this work."
Funding Disclosure
Evidence found in paper:
"This study was supported by Hunan Pharmaceutical Association Foundation (No: 2020YXH001), Hunan Provincial Natural Science Foundation of China (No: 2021JJ70025), and Climbing Plan of Hunan Cancer Hospital (No: 2021NSFC-A003)."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025